Abstract:Acute promyelocytic leukemia (APL) is an interesting model in cancer research, because it can respond to the differentiation/apoptosis induction therapy using all-trans retinoic acid (ATRA) and arsenic trioxide (As(2)O(3)). Over the past 5 years, it has been well demonstrated that As(2)O(3) induces a high complete remission (CR) rate in both primary and relapsed APL patients (around 85 to 90%). The side effects are mild to moderate in relapsed patients, while severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As(2)O(3) as post-remission therapy has given better survival than those treated with As(2)O(3) alone. The effect of As(2)O(3) has been shown to be related to the expression of APL-specific PML-RARalpha oncoprotein, and there is a synergistic effect between As(2)O(3) and ATRA in an APL mouse model. Cell biology studies have revealed that As(2)O(3) exerts dose-dependent dual effects on APL cells. Apoptosis is evident when cells are treated with 0.5 approximately 2.0 microM of As(2)O(3) while partial differentiation is observed using low concentrations (0.1 approximately 0.5 microM) of the drug. The apoptosis-inducing effect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the mechanisms underlying APL cell differentiation induced by low dose arsenic remain to be explored. Interestingly, As(2)O(3) over a wide range of concentration (0.1 approximately 2.0 microM) induces degradation of a key leukemogenic protein, PML-RARalpha, as well as the wild-type PML, thus setting up a good example of targeting therapy for human cancers.

Promyelocytic Leukemia Protein Induces Arsenic Trioxide Resistance Through Regulation of Aldehyde Dehydrogenase 3 Family Member A1 in Hepatocellular Carcinoma

Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients

High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.

Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy

Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1 alpha Expression

Arsenic Trioxide Inhibits The Hedgehog Pathway Which Is Aberrantly Activated In Acute Promyelocytic Leukemia

Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML

Arsenic trioxide regulates the glycolytic pathway to treat acute promyelocytic leukemia by inhibiting RPL22L1

Balance Between the Toxicity and Anticancer Activity of Arsenic Trioxide in Treatment of Acute Promyelocytic Leukemia.

Parthenolide and arsenic trioxide co-trigger autophagy-accompanied apoptosis in hepatocellular carcinoma cells

Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.

Varying Responses of PML-RARA with Different Genetic Mutations to Arsenic Trioxide.

Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression

Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond

Arsenic Trioxide Preferentially Binds to the Ring Finger Protein PML: Understanding Target Selection of the Drug

Arsenic Trioxide Targets Hsp60, Triggering Degradation Of P53 And Survivin

Pyrrolidine Dithiocarbamate Enhances the Cytotoxic Effect of Arsenic Trioxide on Acute Promyelocytic Leukemia Cells.

Early Application Of Arsenic Trioxide Improved The Clinical Outcomes Of Acute Promyelocytic Leukemia

Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex

Biotransformation of Arsenic Trioxide by AS3MT Favors Eradication of Acute Promyelocytic Leukemia: Revealing the Hidden Facts

Arsenic trioxide, a therapeutic agent for APL.